Skip to main content
Figure 1 | Translational Neurodegeneration

Figure 1

From: The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson’s disease: a randomized, double-blind, double-dummy, parallel-group study

Figure 1

Improvement in UPDRS II + III scores in both arms. (A) Adjusted mean change (±SE) in UPDRS II + III score over time, full analysis set (FAS) (last observation carried forward, LOCF). Since the lower limit of the 2-sided confidence interval for treatment difference was higher than the non-inferiority margin, pramipexole ER was non-inferior to pramipexole IR. (B) Percentage of UPDRS II + III responder patients over time, FAS (LOCF). At week 18, the response rate was slightly higher in the ER arm than in the IR arm, but without a statistically significant difference between the arms.

Back to article page

Translational Neurodegeneration

ISSN: 2047-9158

Contact us